MoringaBase
Back to research

Formulasi dan Evaluasi Fisik Suspensi Topikal Ekstrak Daun Kelor (Moringa oleifera L.) dalam Pengembangan Sediaan Antijamur Herbal

Desti Kameliani, Meilina Putri, Sukmawati Sukmawati

JURNAL ILMIAH KESEHATAN MASYARAKAT DAN SOSIAL12 June 2026
View paper DOI: 10.59024/jikas.v4i3.1764
15
Exploratory
In VitroMixedSkin/TopicalAntimicrobial

Desti Kameliani, Meilina Putri, Sukmawati Sukmawati (2026). Formulasi dan Evaluasi Fisik Suspensi Topikal Ekstrak Daun Kelor (Moringa oleifera L.) dalam Pengembangan Sediaan Antijamur Herbal. JURNAL ILMIAH KESEHATAN MASYARAKAT DAN SOSIAL. doi:10.59024/jikas.v4i3.1764

Fungal skin infections caused by a yeast called Malassezia furfur are a persistent problem in tropical climates, where warm, humid conditions allow the organism to thrive. Researchers in Indonesia set out to explore whether an extract from moringa (Moringa oleifera) leaves could be turned into a stable, usable topical suspension — essentially a liquid medicine applied to the skin — with genuine antifungal potential. The team created four versions of the suspension: a control formula with no extract, and three active formulas containing 9%, 10%, and 11% moringa leaf extract. They then put each formula through a battery of physical tests — checking appearance, smell, texture, how evenly the extract was distributed through the liquid, acidity (pH), thickness (viscosity), and how well the preparation stuck to skin (adhesiveness). Stability was assessed over 12 days using a cycling test, which repeatedly shifts the product between warm and cool temperatures to simulate storage stress. All three active formulas passed the basic physical quality checks: they looked acceptable, mixed evenly, and fell within the pH range considered safe for skin contact. However, pH drifted slightly during storage, and adhesiveness varied across testing cycles, suggesting the formulas are not yet fully stable. The researchers concluded that moringa leaf extract can be incorporated into a topical suspension at these concentrations without immediate physical failure, but that further work is needed to lock in stability before the product could be considered ready for real-world use. No antifungal efficacy testing against live Malassezia furfur was conducted in this study.

Study details

Population

In vitro formulation study — no human or animal subjects. Four laboratory-prepared topical suspension formulations (F0 control, F1 9% extract, F2 10% extract, F3 11% moringa leaf extract) evaluated under controlled laboratory conditions. Target pathogen context: Malassezia furfur (cutaneous fungal infection), though no live organism testing was conducted in this study.

Duration

12 days

Plant part

Leaf

Preparation

Extract Other

Country

Indonesia

Dosage protocol

Topical suspension formulations tested at three extract concentrations: 9% (F1), 10% (F2), and 11% (F3) moringa leaf extract; applied concentration in a suspension vehicle for skin application; frequency, volume per application, and duration of use not specified in abstract as this was a physical formulation study with no human or animal application

Key compounds

flavonoidstanninssaponins

Original paper

Related studies